Drug intelligence / Profile preview

Cilnipres

Development stage
Unknown
Lead developer
East West Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Cilnipres is a small molecule antihypertensive medication containing the active ingredient cilnidipine, a fourth-generation calcium channel blocker. Unlike traditional calcium channel blockers that primarily target L-type channels, Cilnipres acts as a dual antagonist of both L-type and N-type voltage-gated calcium channels. By blocking L-type channels in the vascular smooth muscle, it induces vasodilation and reduces peripheral resistance. Its action on N-type channels, located on sympathetic nerve endings, inhibits the release of norepinephrine, thereby suppressing sympathetic overactivity and providing additional cardioprotective and renoprotective benefits. Developed and marketed by East West Pharma, it is approved for the management of hypertension and the prevention of angina pectoris.

Brand names
Cilnipres
Other names
cilnidipine
02

Targets

CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on Cilnipres.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cilnipres.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call